Oramed Pharmaceuticals Inc.

Company Snapshot: Oramed Pharmaceuticals Inc.

Last Change Volume High Low

Company Overview

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed’s Protein Oral Delivery (POD™) technology is based on over 30 years of research by top scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). The Company completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901).

Client News

  1. Jul 26 2022 Oramed Reaches 50% Enrollment in its Second Phase 3 Oral Insulin Trial
  2. Jul 11 2022 Oramed to Present at the Upcoming Canaccord Genuity Annual Growth Conference
  3. Jul 7 2022 Oramed Letter to Shareholders
  4. Jun 1 2022 Oramed Appoints Dr. Anne Peters to its Scientific Advisory Board